The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The neuropsychopharmacology of cannabis: A review of human imaging studies
Open accessAbstract
receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 2×
“Larger-scale publicallyavailable data sets with many hundreds of subjects such as the Human Connectome Project (HCP; e.g. Pagliaccio, et al., 2015) and the UK Biobank (Sudlow et al., 2015) are also beginning to address the issues of small sample sizes and low experimental power.”
BackgroundPower failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641 · cited 2×
“There is an emerging awareness that many neuroscience studies may be severely under-powered in a statistical sense (Button et al., 2013; Nord et al., 2017) and neuroimaging studiesmay be particular examples, because their relatively high cost (in both money, and researcher time) make collecting large samples difficult.”
BackgroundInsensitivity to future consequences following damage to human prefrontal cortex
Bechara, A., Damasio, A. R., Damasio, H., & Anderson, S. W. (1994) · Cognition · doi:10.1016/0010-0277(94)90018-3 · Cited by 6,128 · cited 5×
“Using the Iowa Gambling Task (Bechara et al., 1994) and H2[(15)O]- PET (Bolla et al.”
MethodInfluentialfMRIPrep: A robust preprocessing pipeline for functional MRI
Esteban, O., Markiewicz, C. J., Blair, R. W., Moodie, C. A., Isik, A. I., Erramuzpe, A., Kent, J. D., Goncalves, M., DuPre, E., Snyder, M., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0235-4 · Cited by 3,905
Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
Eklund, A., Nichols, T. E., & Knutsson, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602413113 · Cited by 3,487 · cited 1×
“Recent high-profile work has highlighted somewhat more subtle, but important, statistical issues (Eklund et al., 2016) which may also contribute to the production of false-positive results in the literature.”
BackgroundCannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 28×
“No significant change Ford et al. (2014) fMRI 15 [cannabis users]/15 [MDD]/14 [cannabis users with MDD]/17 [healthy controls] - Music Listening Paradigm (Neutral and Preferred Music) 20.2 (1.3) [cannabis users], 19.9 (1.7) [MDD + cannabis users] 6.8 (0.4) [cannabis users] 6.9 (0.4) [cannabis users + MDD] - 22.0 (6.2)…”
BackgroundInfluentialTrial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 1×
“With its excellent safety and tolerability profile and lack of intoxicating effects, CBD has generated significant interest as a novel treatment for psychosis, (Leweke et al., 2012; McGuire et al., 2017) epilepsy”
BackgroundGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · cited 9×
“When administered alone, CBD has minimal activity at CB1Rs, but it can inhibit the effects of cannabinoid agonists by acting as a negative allosteric modulator of CB1Rs (Laprairie et al., 2015).”
BackgroundInfluentialEffect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Self-citationPhytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 1×
“, 2018), anxiety disorders (Bergamaschi et al., 2011; Crippa et al., 2004) and addictions (Hindocha, Freeman, et al.”
BackgroundKatona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 28×
“No significant change Ford et al. (2014) fMRI 15 [cannabis users]/15 [MDD]/14 [cannabis users with MDD]/17 [healthy controls] - Music Listening Paradigm (Neutral and Preferred Music) 20.2 (1.3) [cannabis users], 19.9 (1.7) [MDD + cannabis users] 6.8 (0.4) [cannabis users] 6.9 (0.4) [cannabis users + MDD] - 22.0 (6.2)…”
BackgroundInfluentialSocial cognitive development during adolescence
Choudhury, S., Blakemore, S.-J., & Charman, T. (2006) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsl024 · Cited by 602
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598 · cited 1×
“006 in neuropathic and chronic pain (Abrams et al., 2007; Mucke et al., 2018; Narang et al., 2008; Svendsen et al., 2004; Wilsey et al., 2008), anti-emetic properties in cancer (Davis, 2016; Smith, Azariah, et al.”
BackgroundHirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.82 · Cited by 587
Meta-analysis of the P300 and P50 waveforms in schizophrenia
BRAMON, E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.004 · Cited by 569
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406 · cited 1×
“Thirdly, oral consumption generally leads to slower absorption and lower bioavailability of THC, and a delay in the onset of acute behavioural effects compared to inhalation (Agurell et al., 1986; Grotenhermen, 2003).”
BackgroundLuijten, M., Schellekens, A. F., Kühn, S., Machielse, M. W. J., & Sescousse, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3084 · Cited by 402
Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0335 · Cited by 391 · cited 4×
“An additional meta-analysis of 69 studies found that cognitive impairments in frequent userswere of a small effect size, and found no evidence for impairment aftermore than 72hours of abstinence (Scott et al., 2018).”
BackgroundInfluentialAssociation Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Bossong, M. G., & Niesink, R. J. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.010 · Cited by 333
Self-citationA randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327 · cited 1×
“006 in neuropathic and chronic pain (Abrams et al., 2007; Mucke et al., 2018; Narang et al., 2008; Svendsen et al., 2004; Wilsey et al., 2008), anti-emetic properties in cancer (Davis, 2016; Smith, Azariah, et al.”
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Cousijn, J., Wiers, R. W., Ridderinkhof, K. R., van den Brink, W., Veltman, D. J., & Goudriaan, A. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.046 · Cited by 287
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy
Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.10.018 · Cited by 257 · cited 1×
“006 in neuropathic and chronic pain (Abrams et al., 2007; Mucke et al., 2018; Narang et al., 2008; Svendsen et al., 2004; Wilsey et al., 2008), anti-emetic properties in cancer (Davis, 2016; Smith, Azariah, et al.”
BackgroundCannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans
Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5603-07.2008 · Cited by 251
Gilman, J. M., Kuster, J. K., Lee, S., Lee, M. J., Kim, B. W., Makris, N., van der Kouwe, A., Blood, A. J., & Breiter, H. C. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4745-13.2014 · Cited by 250 · cited 1×
“Findings of increased grey matter density in other limbic subcortical structures in young cannabis users may reflect cannabis-induced changes in arborisation (Gilman et al., 2014).”
BackgroundLong-term effects of marijuana use on the brain
Filbey, F. M., Aslan, S., Calhoun, V. D., Spence, J. S., Damaraju, E., Caprihan, A., & Segall, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415297111 · Cited by 249 · cited 2×
“Nonetheless, other studies have found effects on orbitofrontal connectivity whereby structural fractional anisotropy in the forceps minor increased with regular use but then decreased following long-term heavy use (Filbey et al., 2014), which would support an effect of drug use on structural connectivity.”
BackgroundResultDuman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure
Levine, A., Clemenza, K., Rynn, M., & Lieberman, J. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.12.014 · Cited by 239
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
The Role of cannabinoids in neuroanatomic alterations in cannabis users.
Lorenzetti, V., Solowij, N., & Yücel, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.013 · Cited by 208
Howes, O. D., & Kapur, S. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.138578 · Cited by 203
Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users
Nestor, L., Hester, R., & Garavan, H. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.07.022 · Cited by 186
United Nations Office on Drugs and Crime (2018) · World Drug Report · doi:10.18356/d29e3f27-en · Cited by 179
Arnone, D., Barrick, T. R., Chengappa, S., Mackay, C. E., Clark, C. A., & Abou-Saleh, M. T. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.064 · Cited by 178 · cited 1×
“One of the three early diffusion tensor imaging studies found evidence of structural dysconnectivity in cannabis users (Arnone et al., 2008; Delisi et al., 2006; Gruber & Yurgelun-Todd, 2005) in the form of reducedmeandiffusivity in the prefrontal section of the corpus callosum.”
BackgroundFusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M. L., O'Carrol, C., Atakan, Z., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990617 · Cited by 163
Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.020 · Cited by 162
Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use
Ashtari, M., Cervellione, K., Cottone, J., Ardekani, B. A., & Kumra, S. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.12.002 · Cited by 159
Adverse Effects of Cannabis on Adolescent Brain Development: A Longitudinal Study
Camchong, J., Lim, K. O., & Kumra, S. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw015 · Cited by 138 · cited 1×
“A separate, longitudinal study of resting functional connectivity in adolescents demonstrated dysconnectivity between the caudal ACC, dorsolateral and orbitofrontal cortices over an 18 month follow-up period (Camchong et al., 2017).”
BackgroundCousijn, J., Wiers, R. W., Ridderinkhof, K. R., van den Brink, W., Veltman, D. J., & Goudriaan, A. E. (2014) · Human Brain Mapping · doi:10.1002/hbm.22342 · Cited by 125
Sevy, S., Smith, G. S., Ma, Y., Dhawan, V., Chaly, T., Kingsley, P. B., Kumra, S., Abdelmessih, S., & Eidelberg, D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1075-1 · Cited by 83
Shared Predisposition in the Association Between Cannabis Use and Subcortical Brain Structure
Pagliaccio, D., Barch, D. M., Bogdan, R., Wood, P. K., Lynskey, M. T., Heath, A. C., & Agrawal, A. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1054 · Cited by 77
Involvement of the endocannabinoid system in reward processing in the human brain
van Hell, H. H., Jager, G., Bossong, M. G., Brouwer, A., Jansma, J. M., Zuurman, L., van Gerven, J., Kahn, R. S., & Ramsey, N. F. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2428-8 · Cited by 77
Self-citationJager, G., Block, R. I., Luijten, M., & Ramsey, N. F. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.785837 · Cited by 66
Jansma, J. M., van Hell, H. H., Vanderschuren, L. J. M. J., Bossong, M. G., Jager, G., Kahn, R. S., & Ramsey, N. F. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.6 · Cited by 58
Cited by
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Self-citationFischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., Brink, W. V. D., et al. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103381 · Cited by 236
“PWUC should generally be aware that there are multiple possible risk-factors or -behaviors that determine their odds of experiencing adverse health outcomes from cannabis use, and that they should aim to avoid as many of these as possible to lower their risk for experiencing acute or chronic harm.”
BackgroundInfluentialAdolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence
Lorenzetti, V., Hoch, E., & Hall, W. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.03.012 · Cited by 166
Burggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1634086 · Cited by 144
Metadata
- Authors
- Bloomfield, M. A. P., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, M. O., Bossong, M. G., & Freeman, T. P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 195
- Pages
- 132-161
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2897774008
- Cited by
- 230
- References
- 55
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.